Thursday, September 16, 2010

Multiple Sclerosis Society of Canada 
National News Releases
Toronto, Ontario - September 16, 2010 – The Multiple Sclerosis Society of Canada board of directors unanimously approved a motion to reserve $1 million for a chronic cerebrospinal venous insufficiency (CCSVI) and MS pan-Canadian therapeutic clinical trial. The funding will be set aside so that an immediate infusion of funding will be available when such a trial is developed and approved.
"We want to hit the ground running when a therapeutic trial is warranted and approved," says Yves Savoie, president and CEO of the MS Society. "Ensuring funds are available to support a Canadian trial more here
Bookmark and Share
Enhanced by Zemanta